Company Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease.
The company also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders, including obesity and type 2 diabetes.
In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease.
The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.
Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2022 |
| IPO Date | Oct 25, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Jeffrey Finer |
Contact Details
Address: 250 East Grand Avenue South San Francisco, California 94080 United States | |
| Phone | 650 338 3533 |
| Website | septerna.com |
Stock Details
| Ticker Symbol | SEPN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001984086 |
| CUSIP Number | 81734D104 |
| ISIN Number | US81734D1046 |
| Employer ID | 84-3891440 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeffrey T. Finer M.D., Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Elizabeth P. Bhatt M.B.A., M.S. | Chief Operating Officer |
| Samira Shaikhly | Chief People Officer |
| Dr. Daniel Long DPHIL | Senior Vice President of Drug Discovery |
| Uwe Klein Ph.D. | Senior Vice President of Biological Sciences |
| Dr. Robert J. Lefkowitz M.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Dr. Arthur Christopoulos BPHARM, Ph.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Dr. Patrick Sexton Ph.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Gilbert M. Labrucherie C.F.A., J.D. | Chief Financial Officer |
| Richard Hansen Ph.D. | Vice President of Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 13, 2025 | SCHEDULE 13G | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |
| Nov 20, 2024 | 10-Q | Quarterly Report |